Professor Kevin Winthrop, MD, MPH

Professor of Infectious Diseases, Ophthalmology,
Professor of Public Health and Preventive Medicine (joint appointment),
Division of Infectious Diseases, OHSU
Oregon Health and Sciences University
Portland, Oregon, USA

Video

Professor Winthrop, can you kindly introduce yourself and share with us your role at Oregon Health Sciences University? And what you plan to cover in this landmark iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Professor Kevin Winthrop, MD, MPH

Video

Can you discuss the current burden of NCFBE and the unmet need for the healthcare system? How do we address high disease burden, increasing prevalence, and profoundly impaired quality of life in NCFBE?

Professor Kevin Winthrop, MD, MPH

Video

Even with the introduction of new inflammation-reducing agents such as brensocatib, what do you envision will be the role of antibiotics as a mainstay in the NCFBE toolkit?

Professor Kevin Winthrop, MD, MPH

Video

Given NCFBE’s global heterogeneity, what key underlying causes—particularly chronic infection—and how identifying these drivers and endotypes can enhance early detection, guide targeted treatment, and improve confirmation of this severe lung disease?

Professor Kevin Winthrop, MD, MPH

Video

What are the non-negotiable features, symptoms, test results, and findings that confirm the diagnosis of NCFBE and therefore make persons potential candidates for inflammation-targeting therapy with such drugs as brensocatib?

Professor Kevin Winthrop, MD, MPH

Video

Given the results of the WILLOW and ASPEN trials, how do you recommend we identify those persons with documented NCFBE who represent ideal candidates for this therapeutic approach?

Professor Kevin Winthrop, MD, MPH

Video

Given the statistically significant improved FEV1 outcomes in of the 25mg vs 10mg dose of brensocatib, and virtually equivalent side effect profiles of the two dosing regimens, how do you use the data to guide your use, dose-wise, of brensocatib?

Professor Kevin Winthrop, MD, MPH

Video

How are brenscocatib and other investigational drugs in the pipeline shaping/changing the multimodal treatment landscape for NCFBE?

Professor Kevin Winthrop, MD, MPH

Video

How should clinicians monitor the success, or lack of success, of brensocatib therapy, once a patient has been committed to this treatment?

Professor Kevin Winthrop, MD, MPH

Video

Can you explain the importance of neutrophil-mediated inflammation as a driver of the pathobiology of NCFBE, and the implications of approaches that mitigate the effects of this progressive process across the heterogeneous spectrum?

Professor Kevin Winthrop, MD, MPH

Video

What are the non-negotiable features, symptoms, test results, and findings that confirm the diagnosis of NCFBE and, by extension, therefore make persons potential candidates for inflammation-targeting therapy with such drugs as brensocatib?

Professor Kevin Winthrop, MD, MPH

Video

Which elements of the ASPEN and WILLOW trial designs best help clinicians identify NCFBE patients likely to benefit from brensocatib and offer an evidence-based framework for monitoring them during treatment?

Professor Kevin Winthrop, MD, MPH